BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 38015476)

  • 1. Chromatin accessibility and pioneer factor FOXA1 restrict glucocorticoid receptor action in prostate cancer.
    Helminen L; Huttunen J; Tulonen M; Aaltonen N; Niskanen EA; Palvimo JJ; Paakinaho V
    Nucleic Acids Res; 2024 Jan; 52(2):625-642. PubMed ID: 38015476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TLE3 loss confers AR inhibitor resistance by facilitating GR-mediated human prostate cancer cell growth.
    Palit SA; Vis D; Stelloo S; Lieftink C; Prekovic S; Bekers E; Hofland I; Šuštić T; Wolters L; Beijersbergen R; Bergman AM; Győrffy B; Wessels LF; Zwart W; van der Heijden MS
    Elife; 2019 Dec; 8():. PubMed ID: 31855178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FoxA1 specifies unique androgen and glucocorticoid receptor binding events in prostate cancer cells.
    Sahu B; Laakso M; Pihlajamaa P; Ovaska K; Sinielnikov I; Hautaniemi S; Jänne OA
    Cancer Res; 2013 Mar; 73(5):1570-80. PubMed ID: 23269278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of the glucocorticoid receptor via a BET-dependent enhancer drives antiandrogen resistance in prostate cancer.
    Shah N; Wang P; Wongvipat J; Karthaus WR; Abida W; Armenia J; Rockowitz S; Drier Y; Bernstein BE; Long HW; Freedman ML; Arora VK; Zheng D; Sawyers CL
    Elife; 2017 Sep; 6():. PubMed ID: 28891793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FOXA1 regulates androgen receptor variant activity in models of castrate-resistant prostate cancer.
    Jones D; Wade M; Nakjang S; Chaytor L; Grey J; Robson CN; Gaughan L
    Oncotarget; 2015 Oct; 6(30):29782-94. PubMed ID: 26336819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Glucocorticoid Receptor Is a Key Player for Prostate Cancer Cell Survival and a Target for Improved Antiandrogen Therapy.
    Puhr M; Hoefer J; Eigentler A; Ploner C; Handle F; Schaefer G; Kroon J; Leo A; Heidegger I; Eder I; Culig Z; Van der Pluijm G; Klocker H
    Clin Cancer Res; 2018 Feb; 24(4):927-938. PubMed ID: 29158269
    [No Abstract]   [Full Text] [Related]  

  • 7. Pioneer of prostate cancer: past, present and the future of FOXA1.
    Teng M; Zhou S; Cai C; Lupien M; He HH
    Protein Cell; 2021 Jan; 12(1):29-38. PubMed ID: 32946061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chromatin binding of FOXA1 is promoted by LSD1-mediated demethylation in prostate cancer.
    Gao S; Chen S; Han D; Wang Z; Li M; Han W; Besschetnova A; Liu M; Zhou F; Barrett D; Luong MP; Owiredu J; Liang Y; Ahmed M; Petricca J; Patalano S; Macoska JA; Corey E; Chen S; Balk SP; He HH; Cai C
    Nat Genet; 2020 Oct; 52(10):1011-1017. PubMed ID: 32868907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enzalutamide response in a panel of prostate cancer cell lines reveals a role for glucocorticoid receptor in enzalutamide resistant disease.
    Smith R; Liu M; Liby T; Bayani N; Bucher E; Chiotti K; Derrick D; Chauchereau A; Heiser L; Alumkal J; Feiler H; Carroll P; Korkola JE
    Sci Rep; 2020 Dec; 10(1):21750. PubMed ID: 33303959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel steroid receptor phyto-modulator compound a inhibits growth and survival of prostate cancer cells.
    Yemelyanov A; Czwornog J; Gera L; Joshi S; Chatterton RT; Budunova I
    Cancer Res; 2008 Jun; 68(12):4763-73. PubMed ID: 18559523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer.
    Sahu B; Laakso M; Ovaska K; Mirtti T; Lundin J; Rannikko A; Sankila A; Turunen JP; Lundin M; Konsti J; Vesterinen T; Nordling S; Kallioniemi O; Hautaniemi S; Jänne OA
    EMBO J; 2011 Sep; 30(19):3962-76. PubMed ID: 21915096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer.
    Isikbay M; Otto K; Kregel S; Kach J; Cai Y; Vander Griend DJ; Conzen SD; Szmulewitz RZ
    Horm Cancer; 2014 Apr; 5(2):72-89. PubMed ID: 24615402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cooperativity and equilibrium with FOXA1 define the androgen receptor transcriptional program.
    Jin HJ; Zhao JC; Wu L; Kim J; Yu J
    Nat Commun; 2014 May; 5():3972. PubMed ID: 24875621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is the glucocorticoid receptor a key player in prostate cancer?: A literature review.
    Sakellakis M; Flores LJ
    Medicine (Baltimore); 2022 Jul; 101(29):e29716. PubMed ID: 35866830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Three-tiered role of the pioneer factor GATA2 in promoting androgen-dependent gene expression in prostate cancer.
    Wu D; Sunkel B; Chen Z; Liu X; Ye Z; Li Q; Grenade C; Ke J; Zhang C; Chen H; Nephew KP; Huang TH; Liu Z; Jin VX; Wang Q
    Nucleic Acids Res; 2014 Apr; 42(6):3607-22. PubMed ID: 24423874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EP300/CREBBP acetyltransferase inhibition limits steroid receptor and FOXA1 signaling in prostate cancer cells.
    Huttunen J; Aaltonen N; Helminen L; Rilla K; Paakinaho V
    Cell Mol Life Sci; 2024 Apr; 81(1):160. PubMed ID: 38564048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated levels of FOXA1 facilitate androgen receptor chromatin binding resulting in a CRPC-like phenotype.
    Robinson JL; Hickey TE; Warren AY; Vowler SL; Carroll T; Lamb AD; Papoutsoglou N; Neal DE; Tilley WD; Carroll JS
    Oncogene; 2014 Dec; 33(50):5666-74. PubMed ID: 24292680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The expression of glucocorticoid receptor is negatively regulated by active androgen receptor signaling in prostate tumors.
    Xie N; Cheng H; Lin D; Liu L; Yang O; Jia L; Fazli L; Gleave ME; Wang Y; Rennie P; Dong X
    Int J Cancer; 2015 Feb; 136(4):E27-38. PubMed ID: 25138562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer.
    Parolia A; Cieslik M; Chu SC; Xiao L; Ouchi T; Zhang Y; Wang X; Vats P; Cao X; Pitchiaya S; Su F; Wang R; Feng FY; Wu YM; Lonigro RJ; Robinson DR; Chinnaiyan AM
    Nature; 2019 Jul; 571(7765):413-418. PubMed ID: 31243372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgen receptor-independent function of FoxA1 in prostate cancer metastasis.
    Jin HJ; Zhao JC; Ogden I; Bergan RC; Yu J
    Cancer Res; 2013 Jun; 73(12):3725-36. PubMed ID: 23539448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.